couldn’t that just mean that the test is most well suited to stopping disease in individuals that are considered low risk which would be a lot of type 2 diabetics? I don’t see how those two statements from NICE and MSAC are so different? The aim is to stop end stage renal failure in people who would normally be considered low risk and aren’t captured until it’s too late? Thoughts?
Ann: PromarkerD application for Australian MBS to be resubmitted, page-39
Add PIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.030(3.03%) |
Mkt cap ! $133.5M | |||
| Open | High | Low | Value | Volume |
| 99.0¢ | $1.02 | 99.0¢ | $43.52K | 43.28K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 12500 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 46627 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.01 |
Change
0.030 ( 2.03 %) |
||||
| Open | High | Low | Volume | ||
| $1.01 | $1.02 | $1.00 | 13629 | ||
| Last updated 15.54pm 24/05/2024 ? | |||||
| PIQ (ASX) Chart |